Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy

British Journal of Ophthalmology

Volumn 95, Issue 4, 2011, Pages 530-533

  Kumar, A ^a   Sahni, J N ^a   Stangos, A N ^a   Campa, C ^a   Harding, S P ^a,b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTRAST SENSITIVITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EYE REFRACTION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RETINA FOVEA; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SIDE EFFECT; SUBRETINAL FLUID; TERTIARY HEALTH CARE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 79952992311     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.171868     Document Type: Article

References (18)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
2. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 1995;102:205-10.
3. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
4. National Institute for Clinical Excellence. Macular degeneration (age-related) - ranibizumab and pegaptanib. Technology appraisals TA 155, 2008. http://www.nice.org.uk/nicemedia/live/11700/40254/40254.pdf (accessed 29 Jul 2010).
5. Ferrara N, Damico L, Shams N, et al. Development of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. (Pubitemid 44547437)
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
8. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An OCT guided, variable dosing regimen with intravitreal Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
9. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for Ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-7.
10. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with Ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409-13.
11. Rothenbuehler SP, Waeber D, Brinkman CK, et al. Effects of Ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-7.
12. Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration; from randomized trials to clinical practice. Eye 2009;23:1633-40.
13. European Public Assessment Report (EPAR). Lucentis summary for the public: EMEA/H/C/715. http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H- 715-en1.pdf (accessed 6 Sep 2009).
14. Chan A, Duker J, Ko TH, et al. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 2006;124:193-8. (Pubitemid 43247068)
15. Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75.
16. Sadda SR, Wu Z, Walsh AC, et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006;113:285-93. (Pubitemid 43170778)
17. Sahni J, Stanga P, Wong D, et al. Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study. Br J Ophthalmol 2005;89:316-20. (Pubitemid 40327616)
18. Arias L, Armada F, Donate J, et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 2009;23:326-33.